article thumbnail

FDA clarifies cybersecurity recommendations for device makers in new guidance

Healthcare Dive

The draft guidance, which replaces a 2018 document, sets recommendations for how medical device companies should approach cybersecurity in premarket submissions.

FDA 335
article thumbnail

FDA Releases Updated Guidance on Medical Device Cybersecurity

HIPAA Journal

Food and Drug Administration (FDA) has issued new draft guidance for medical device manufacturers to help them incorporate cybersecurity protections into their products at the premarket stage, and to ensure security risks are managed for the full life cycle of the products. The FDA will then work on a final version of the guidance.

FDA 126
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis wins FDA OK for radiopharmaceutical drug, cashing in on Endocyte deal

Healthcare Dive

billion buyout of Endocyte in 2018. The approval of Pluvicto for prostate cancer is a notable step forward for the field of radiopharmaceutical therapy and validates the Swiss drugmaker's $2.1

FDA 196
article thumbnail

The FDA Ramps Up GMP Inspections

Dot Compliance

Prior to the COVID-19 pandemic, during fiscal year (FY) 2019 (October 1, 2018, through September 30, 2019), the FDA conducted 7,266 GMP inspections of registered drug, device and biologics establishments. Compliance Dashboard, Inspections, FDA, accessed October 3, 2022, [link] cd/inspections.htm ).

FDA 52
article thumbnail

The FDA Releases New Draft Guidance on Considering Health Care Disparities When Reviewing Proposed Devices

C&M Health Law

Food and Drug Administration (FDA) released a draft guidance that, if finalized, will update the agency’s 2018 guidance on its Breakthrough Devices Program (the “Program”). If this latest draft guidance is finalized after a period of public comment, the agency will incorporate the proposed language into the 2018 guidance.

FDA 52
article thumbnail

FDA Issues Final Guidance on Informed Consent for IRBs, Clinical Investigators, and Sponsors

Health Law Advisor

Food and Drug Administration (“FDA”) released final guidance on informed consent for clinical investigations (“Final Guidance”). This update follows FDA’s draft guidance, which was issued in July 2014, and supersedes the FDA’s “A Guide to Informed Consent,” which was issued in September 1998. On August 15, 2023, the U.S.

article thumbnail

FDA Considers New Approach to Improve Safe Disposal of Prescription Opioid Analgesics

Sharps Compliance

Between 2010 and 2018, there were 48,000 accidental prescription opioid exposures among young children.3. Continue reading FDA Considers New Approach to Improve Safe Disposal of Prescription Opioid Analgesics at Sharps Compliance Blog.

FDA 82